id=44). In January 2005, the U.S. Food and Drug Administration licensed a new tetravalent meningococcal conjugate vaccine ([MCV4] Menactra) for use in people 11-55 years of age. MCV4 contains ...
In 2005, the quadrivalent meningococcal vaccine MCV4 (Menactra; Sanofi Pasteur) — which contains N. meningitidis serogroup A, C, Y and W-135 polysaccharides conjugated individually to diphtheria ...
Even people familiar with meningococcal disease are astonished at the rapidity with which this rare though deadly illness can ravage the body. Within hours, patients can go from perfectly healthy ...
An immunization within the last 10 years for Tetanus/Diphtheria (Td/Tdap). If under the age of 23, a quadrivalent meningococcal conjugate vaccine (MCV4) on or after your 16th birthday. Acceptable ...
Birth in the U.S. before 1980 acceptable only for non-health science students Meningococcal conjugate quadrivalent (A,C,Y,W-135) (Menactra, Menveo or Nimenrix only) 1 dose; 1 dose MenACWY (formerly ...
In January 2005, Food and Drug Administration licensed a new tetravalent (serogroups A, C, Y, W-135) meningococcal conjugate vaccine ([MCV4] Menactra) for use in persons 11-55 years of age.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback